PCI Synthesis Sponsors Massachusetts Biotechnology Council, Inc.'s Massachusetts CRO/CMO Symposium
NEWBURYPORT, MA--(Marketwire - February 15, 2012) -
PCI Synthesis Capabilities
"Unique among bio clusters nationwide, Massachusetts has a strong life science ecosystem where small and large developers of new therapeutics can access locally based, high technology solution providers with expertise in every aspect of drug development and manufacturing," said Edward S. Price, President of PCI and co-chair of MassBio's new Massachusetts CRO/CMO Committee. "The local CRO/CMO community serves as a center of excellence, sharing best practices and insights, and providing mutual resources. Every aspect of drug development and manufacturing, from post discovery through commercialization, can be outsourced here. Efficiencies achieved by operating locally include improved communication and project management -- improving timelines, creating new efficiencies, and driving costs lower while accelerating overall development."
The symposium is designed to give attendees exposure to best practices in accelerating time-to-market strategies by leveraging Boston-based expertise, including presentations by Josef H. von Rickenbach, Chair of the Board, CEO and Founder of PAREXEL International; Karen N. Archdeacon, Compliance Officer, FDA New England District; and Tim Murray, Lieutenant Governor of Massachusetts, discussing "Job Creation in This Economic Climate." Case studies, panel discussions and networking sessions will allow attendees to hear from both brick-and-mortar and virtual life science companies that have found success in Massachusetts. An exhibition area will feature more than 30 Boston-based researchers, suppliers and technical solution providers that can help attendees take their businesses to the next level.
For more information about the symposium, please visit: http://bit.ly/yA32Bq.
About PCI Synthesis
PCI Synthesis is a 12-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules and APIs used in generic pharmaceuticals. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.